- Report
- October 2024
- 195 Pages
Global
From €3360EUR$3,545USD£2,807GBP
€3733EUR$3,939USD£3,119GBP
- Report
- October 2024
- 187 Pages
Global
From €3360EUR$3,545USD£2,807GBP
€3733EUR$3,939USD£3,119GBP
- Report
- April 2025
- 94 Pages
Global
From €5308EUR$5,600USD£4,434GBP
- Report
- March 2025
- 200 Pages
Global
From €4256EUR$4,490USD£3,555GBP
- Report
- February 2025
- 200 Pages
Global
From €4256EUR$4,490USD£3,555GBP
- Report
- February 2025
- 150 Pages
Global
From €4597EUR$4,850USD£3,840GBP
- Report
- May 2024
- 131 Pages
Global
From €6160EUR$6,499USD£5,146GBP
- Report
- February 2025
- 180 Pages
Global
From €4265EUR$4,500USD£3,563GBP
- Report
- August 2023
- 147 Pages
Global
From €7109EUR$7,500USD£5,939GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1422EUR$1,500USD£1,188GBP
- Report
- August 2022
- 105 Pages
Global
From €4502EUR$4,750USD£3,761GBP
- Report
- October 2023
- 182 Pages
Global
From €4265EUR$4,500USD£3,563GBP
- Report
- November 2020
- 225 Pages
Global
From €14213EUR$14,995USD£11,874GBP
- Drug Pipelines
- September 2020
- 96 Pages
Global
From €1896EUR$2,000USD£1,584GBP
- Report
- October 2023
- 77 Pages
Global
From €3500EUR$3,956USD£3,026GBP
- Report
- August 2022
- 50 Pages
Global
From €1896EUR$2,000USD£1,584GBP
- Report
- June 2022
- 78 Pages
Global
From €1896EUR$2,000USD£1,584GBP
- Report
- April 2025
- 50 Pages
Global
From €2512EUR$2,650USD£2,098GBP

Lanreotide is a medication used to treat endocrine and metabolic disorders. It is a somatostatin analogue, which works by blocking the release of hormones from the pituitary gland. It is used to treat acromegaly, a condition caused by an overproduction of growth hormone, and neuroendocrine tumors, which are tumors that originate in the endocrine system. It is also used to treat carcinoid syndrome, a condition caused by the overproduction of serotonin.
Lanreotide is available in both injectable and capsule forms. The injectable form is administered subcutaneously, while the capsule form is taken orally. The medication is typically taken once or twice a day, depending on the condition being treated.
The lanreotide market is a growing one, with many companies offering the medication. Some of these companies include Novartis, Ipsen, and Teva Pharmaceuticals. Show Less Read more